The class of drugs known as checkpoint inhibitors causes an inflammation of the heart muscles. As the use of the drugs expands, researchers are sure that more people will develop deadly heart conditions. In other pharmaceutical news: FDA approval for rare drugs; lung cancer treatments; lawsuits over antipsychotic drug side effects; and right-to-try legislation.
from Kaiser Health News http://ift.tt/2FXgD9v
March 20, 2018
Rose
Health News, Kaiser Health News
No comments
Related Posts:
‘Into the Covid ICU’: A New Doctor Bears Witness to the Isolation, Inequities of PandemicCan’t see the audio player? Click here to listen on SoundCloud. This story also ran on Reveal. It can be republished for free. This week marks a grim milestone: Half a million Americans have died of covid-19. KHN report… Read More
Black Churches Fill a Unique Role in Combating Vaccine FearsThis story also ran on The Mercury News. It can be republished for free. In the hospital with covid-19 in December, Lavina Wafer tired of the tubes in her nose and wondered impatiently why she couldn’t be discharged. A phone … Read More
Looking to Kentucky’s Past to Understand Montana Health Nominee’s FutureUse Our Content It can be republished for free. The nominee to be Montana’s next health director faced an unwieldy disease outbreak and pushed Medicaid work requirements — two issues looming in Montana — when he held a simila… Read More
Connecticut Is Doling Out Vaccines Based Strictly on Age. It’s Simpler, but Is it Fair?With covid vaccines expected to remain scarce into early spring, Connecticut has scrapped its complicated plans to prioritize immunizations for people under 65 with certain chronic conditions and front-line workers. Instead, … Read More
Beijing’s SARS Lockdown Taught My Children Resilience. Your Covid Kids Will Likely Be Fine. This story also ran on The Washington Post. It can be republished for free. Many parents are filled with angst as they prepare for their children to exit a year of pandemic isolation: Will it be OK to send them to school, pe… Read More
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment